PT - JOURNAL ARTICLE AU - Lv, Meng AU - Wang, Mengshu AU - Yang, Nan AU - Luo, Xufei AU - Li, Wei AU - Chen, Xin AU - Liu, Yunlan AU - Ren, Mengjuan AU - Zhang, Xianzhuo AU - Wang, Ling AU - Ma, Yanfang AU - Lei, Junqiang AU - Fukuoka, Toshio AU - Ahn, Hyeong Sik AU - Lee, Myeong Soo AU - Luo, Zhengxiu AU - Chen, Yaolong AU - Liu, Enmei AU - Tian, Jinhui AU - Wang, Xiaohui AU - , TI - Chest Computed Tomography for the Diagnosis of Patients with Coronavirus Disease 2019 (COVID-19): A Rapid Review and Meta-Analysis AID - 10.1101/2020.04.14.20064733 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.14.20064733 4099 - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20064733.short 4100 - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20064733.full AB - Background The outbreak of the coronavirus disease 2019 (COVID-19) has had a massive impact on the whole world. Computed tomography (CT) has been widely used in the diagnosis of this novel pneumonia. This study aims to understand the role of CT for the diagnosis and the main imaging manifestations of patients with COVID-19.Methods We conducted a rapid review and meta-analysis on studies about the use of chest CT for the diagnosis of COVID-19. We comprehensively searched databases and preprint servers on chest CT for patients with COVID-19 between 1 January 2020 and 31 March 2020. The primary outcome was the sensitivity of chest CT imaging. We also conducted subgroup analyses and evaluated the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.Results A total of 104 studies with 5694 patients were included. Using RT-PCR results as reference, a meta-analysis based on 64 studies estimated the sensitivity of chest CT imaging in COVID-19 was 99% (95% CI, 0.97-1.00). If case reports were excluded, the sensitivity in case series was 96% (95% CI, 0.93-0.99). The sensitivity of CT scan in confirmed patients under 18 years old was only 66% (95% CI, 0.11-1.00). The most common imaging manifestation was ground-glass opacities (GGO) which was found in 75% (95% CI, 0.68-0.82) of the patients. The pooled probability of bilateral involvement was 84% (95% CI, 0.81-0.88). The most commonly involved lobes were the right lower lobe (84%, 95% CI, 0.78-0.90) and left lower lobe (81%, 95% CI, 0.74-0.87). The quality of evidence was low across all outcomes.Conclusions In conclusion, this meta-analysis indicated that chest CT scan had a high sensitivity in diagnosis of patients with COVID-19. Therefore, CT can potentially be used to assist in the diagnosis of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from National Clinical Research Center for Child Health and Disorders (Children's Hospital of Chongqing Medical University, Chongqing, China) (grant number NCRCCHD-2020-EP-01) to [Enmei Liu]; Special Fund for Key Research and Development Projects in Gansu Province in 2020, to [Yaolong Chen]; The fourth batch of “Special Project of Science and Technology for Emergency Response to COVID-19” of Chongqing Science and Technology Bureau, to [Enmei Liu]; Special funding for prevention and control of emergency of COVID-19 from Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province (grant number No. GSEBMKT-2020YJ01), to [Yaolong Chen].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were shown as supplementary materials in the PDF.